Politics,cancer pain,and methadone

Abstract

Get full access to this article

View all access options for this article.

References

Dickerson ED : 20 essential drugs in palliative care. European J Palliative Care. 1999; 6(4): 130.

Bruera E , Neumann CM : Role of methadone in the management of pain in cancer patients. Oncology. 1999; 13(9): 1275.

Mathew P , Storey P : Subcutaneous methadone in terminally ill patients: Manageable local toxicity. J Pain & Symptom Management. 1999; 18(1): 49.

Hagen NA , Wasylenko E : Methadone: Outpatient titration and monitoring strategies in cancer patients. J Pain & Symptom Management. 1999; 18(5): 369.

Scholes CF , Gonty N , Trotman IF : Methadone titration in opioid resistant cancer pain. European J Cancer Care. 1999; 8(1): 26.

Mercadante S , et al. : Morphine versus methadone in the treatment of advanced cancer patients follow up at home. J Clinical Oncology. 1998; 16(11): 3656.

The federal regulations regarding outpatient methadone maintenance therapy can be viewed at: http://www.methadone.org/fedregs.html.

Davis AM , Inturrisi CE : d-Methadone blocks morphine tolerance and NMDA induced hyperalgesia. J Pharm Exp Ther. 1999; 289(2): 1048.

Heusch WL , Maneckjee R : Effects of bombesin on methadone-induced apoptosis of human lung cancer cells. Cancer Lett. 1999; 136(2): 177.

10.

Wheeler WL , Dickerson ED : Pharmaceutical Update: Clinical applications of methadone. American J Hospice & Palliative Care. 2000; 17(3): 196-203.